Study summary · research use only
Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This mouse study (p-chlorophenylalanine [PCPA]-induced insomnia model) examined a delta sleep inducing peptide fused with a Pichia pastoris-secreted blood-brain-barrier-crossing peptide (DSIP-CBBBP), assessing its association with sleep and neurotransmitter levels compared with DSIP alone. The peptide's influence on neurotransmitters including 5-HT, glutamate, dopamine, and melatonin was assessed using biochemical and insomnia-behavior tests. DSIP-CBBBP was reported to be associated with changes in 5-HT, glutamate, dopamine, and melatonin levels, and showed a better restorative effect on neurotransmitter imbalance than DSIP alone, along with an association with increased sleep. The authors describe DSIP-CBBBP as relevant to correcting neurotransmitter dysregulation and sleep-related conditions.
Abstract
Pichia pastoris-secreted delta sleep inducing peptide and crossing the blood-brain barrier peptides (DSIP-CBBBP) fusion peptides holds significant promise for its potential sleep-enhancing and neurotransmitter balancing effects. This study investigates these properties using a p-chlorophenylalanine (PCPA) -induced insomnia model in mice, an approach akin to traditional methods evaluating sleep-promoting activities in fusion peptides. The research aims to elucidate the sleep-promoting mechanism of DSIP-CBBBP, exploring its impact on neurotransmitter levels and sleep regulation, and to analyze its composition and structure. Using a PCPA-induced insomnia mouse model, the study evaluates the sleep-promoting effects of DSIP-CBBBP. The peptide's influence on neurotransmitters such as 5-HT, glutamate, dopamine, and melatonin is assessed. The functions of DSIP-CBBBP are characterized using biochemical and animal insomnia-induced behavior tests and compared without CBBBP. DSIP-CBBBP demonstrates a capacity to modulate neurotransmitter levels, indicated by changes in 5-HT, glutamate, DA, and melatonin. DSIP-CBBBP shows a better restorative effect than DSIP on neurotransmitter imbalance and the potential to enhance sleep. The study underscores DSIP-CBBBP potential in correcting neurotransmitter dysregulation and promoting sleep, hinting at its utility in sleep-related therapies.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.